Track Group, Inc. TRCK
0.43 USD -0.01 (-2.27%)
Regular-session close
0.43 Day range 0.43
0.17 52-week range 0.81
- YTD
- +43.33%
- 1 year
- +59.26%
No chart data for this range yet.
- Market cap
- 17.77M
- EPS (ttm)
- 1.07
- P/E ratio
- 0.40
- YTD return
- +43.33%
- 1-year return
- +59.26%
- Volume
- 809
- Avg volume
- 10.76K
- Open
- 0.43
- Previous close
- 0.44
- Day's range
- 0.43 – 0.43
- 52-week range
- 0.17 – 0.81
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | 0.13 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.16 | — | — |
| Feb 8, 2024 | Dec 1, 2023 | 0.00 | 0.09 | — | — |
| Dec 20, 2023 | Sep 1, 2023 | 0.00 | 0.09 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | 0.09 | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | -0.13 | — | — |
News
2 Newer Monthly Paycheck ETFs vs. a Veteran: Does a Short Track Record Matter?
Dario Amodei Predicted at Davos in January 2025 That AI Could Surpass Humans “at Almost Everything” Within Two to Three Years. With Anthropic Now Filing for a $1.4 Trillion IPO, Is That Timeline Still on Track?
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
Teamshares Reports 3Q 2026 Results; Remains On-Track to Meet 2026 Outlook
Creative Realities Reports Fiscal 2026 Third Quarter Results
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
i-80 Gold: Development Remains On Track, And The Stock Offers Great Value
Your note
Sign in to keep a note on TRCK — it syncs with the Stock Master app.
